|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.400 USD | -0.74% |
|
-5.62% | -10.48% |
| 07-16 | Moderna advances its cancer therapy assessment, but the stock slides |  |
| 06-01 | Immatics N.V. Announces Updated Clinical Data For IMA203CD8, IMA401, And Anzu-Cel PRAME Cell Therapies | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.28B | - | ||||
| 55.98B | |||||
| 53.69B | |||||
| 23.29B | - | ||||
| 23.15B | - | ||||
| 20.58B |
- Stock Market
- Stocks
- IMTX Stock
- Charts Immatics N.V.
- Sector Chart
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
